Alnylam Pharmaceuticals (ALNY) Change in Acquisitions & Divestments (2009 - 2026)

Alnylam Pharmaceuticals' Change in Acquisitions & Divestments history runs 18 years deep, the most recent figure standing at $213.2 million for Q1 2026.

• Quarterly Change in Acquisitions & Divestments fell 59.34% year-over-year to $213.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$251.4 million (down 215.97% YoY) and the FY2025 annual result came in at $59.8 million, up 3.28% from the prior year.
• Change in Acquisitions & Divestments was $213.2 million for Q1 2026 at Alnylam Pharmaceuticals, up from -$1.5 billion in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $1.6 billion in Q3 2022 and bottomed at -$1.5 billion in Q4 2022.
• A 5-year average of $30.0 million and a median of $131.2 million in 2023 frame the typical range for Change in Acquisitions & Divestments.
• Annual changes were most pronounced in 2022 — Change in Acquisitions & Divestments sank 9705.61% — and 2024, when it jumped 642.44%.
• Alnylam Pharmaceuticals' Change in Acquisitions & Divestments stood at -$1.5 billion in 2022, then jumped by 54.5% to -$699.3 million in 2023, then tumbled by 53.12% to -$1.1 billion in 2024, then sank by 41.99% to -$1.5 billion in 2025, then surged by 114.02% to $213.2 million in 2026.
• Business Quant data shows ALNY's Change in Acquisitions & Divestments at $213.2 million in Q1 2026, -$1.5 billion in Q4 2025, and $1.5 billion in Q3 2025.